On Wednesday, Morgan Stanley made a notable adjustment to its stance on Demant A/S (DEMANT:DC) (OTC: WILYY), shifting the hearing aid company's stock from an 'Underweight' to an 'Overweight' rating. Accompanying this upgrade, the firm also increased the price target for Demant's shares from DKK268.00 to DKK320.00.
The upgrade decision was influenced by several factors, including a significant drop in share price since March 2024, which has seen a 30% decline from the highs of that period. Morgan Stanley anticipates growth to pick up pace heading into 2025 as the company faces easier comparative periods.
The firm also pointed out Demant's successful expansion in the Veterans Affairs (VA) channel, where its market share increased from 16% in January 2023 to 19% by July 2024, boosted by the launch of the Oticon Real and Oticon Intent products.
Furthermore, Morgan Stanley highlighted the divergence in performance between Demant and its competitor Sonova, noting that Demant's shares have underperformed in recent months.
The analyst believes that the market has already accounted for the risks following Demant's previous earnings warning and guidance adjustment, suggesting that the current earnings estimates are largely risk-free.
Another point of consideration for the upgrade was the limited risk to earnings, even in the event of Sonova re-entering the Costco (NASDAQ:COST) sales channel.
Morgan Stanley sees the current valuation of Demant's shares as an attractive entry point, with the stock trading at what they consider trough levels compared to its peers in the hearing aid industry and historical lows when compared to Sonova.
Morgan Stanley's bullish sentiment is further underscored by the firm's view of the stock's risk-reward balance, which they believe is at the higher end of the sector with a 3:1 bull-to-bear skew.
This suggests that the firm sees a favorable upside potential for investors, especially given the significant shift in market sentiment from the highs of March.
In other recent news, Jefferies reduced Demant A/S's price target, citing a weaker-than-expected first-quarter performance. The new price target stands at DKK275.00, reflecting an 11% decrease from the prior target, while the earnings per share forecast for 2024 has been marked down by about 4%. This is primarily attributed to increased financial expenses.
Demant's early year performance has been challenging, as evidenced by tough year-over-year comparisons in its Wholesale division and weaker trends in its Care business, especially in the French market and the United States. Despite these obstacles, Demant has maintained its financial guidance for the year.
Jefferies analysts have maintained a cautious stance on Demant's 2024 earnings outlook, citing factors such as a slight easing of comparatives, a changing mix of channels and countries of operation, and heightened competition.
The decision to reiterate the underperform rating on Demant's shares is also based on the perceived unattractive valuation of the company's stock. These recent developments underscore Demant's challenges in a competitive landscape and varied performance across its markets.
InvestingPro Insights
Demant A/S (OTC: WILYY) has caught the attention of investors and analysts alike with recent strategic moves and market performance. In light of Morgan Stanley's upgrade, an examination of real-time data and InvestingPro Tips provides further insights into the company's financial health and market position. The company's management has demonstrated confidence through an aggressive share buyback program, which could signal a belief in the company's undervalued stock and a commitment to increasing shareholder value.
With a P/E ratio of 25.51, Demant is trading at a low price relative to its near-term earnings growth, indicating potential for investors seeking value in the Healthcare Equipment & Supplies industry. The company's Price / Book multiple, sitting at 6.41, suggests a high valuation of its net assets, which could be a point of consideration for investors assessing the company's market price against its book value. Additionally, Demant's profitability over the last twelve months and predictions from analysts that the company will remain profitable this year provide a reassuring sign of financial stability.
InvestingPro Data reveals a robust revenue growth of 9.25% over the last twelve months as of Q2 2024, and an impressive Gross Profit Margin of 74.61%, which speaks to the company's efficiency in managing its cost of goods sold. Moreover, Demant's Operating Income Margin of 17.57% reflects its ability to convert revenue into operating income effectively.
For those interested in further analysis and tips, InvestingPro offers additional insights, with a total of 7 InvestingPro Tips available, which can be explored for a deeper understanding of Demant's potential investment opportunities. The InvestingPro Fair Value estimate of 22.37 USD also provides an additional reference point for investors considering the stock's current and potential future value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.